DaVita/$DVA

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About DaVita

DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business. Berkshire Hathaway owns about 45% of DaVita.

Ticker

$DVA

Primary listing

NYSE

Industry

Health Care Providers & Services

Employees

76,000

ISIN

US23918K1088

DaVita Metrics

BasicAdvanced
$11B
14.03
$10.11
1.14
-

What the Analysts think about DaVita

Analyst ratings (Buy, Hold, Sell) for DaVita stock.

Bulls say / Bears say

DaVita's expansion into Latin America, including Brazil and Colombia, is expected to drive future growth by tapping into new markets. (Nasdaq)
The company's strong financial performance, with adjusted operating income of $1.98 billion and adjusted EPS of $9.68 in 2024, demonstrates robust profitability. (TipRanks)
DaVita's commitment to returning capital to shareholders through share repurchases indicates confidence in its financial health and future prospects. (TipRanks)
DaVita faces a proposed class action lawsuit alleging anti-competitive practices that could lead to significant legal and financial repercussions. (Reuters)
The company's 2025 earnings guidance fell short of analyst expectations, projecting EPS between $10.20 and $11.30, below the consensus estimate of $11.24, raising concerns about future profitability. (The Motley Fool)
DaVita's treatment volume growth has consistently lagged behind internal expectations, with volume growth challenges persisting due to elevated mortality and mistreatment rates. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Jul 2025.

DaVita Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

DaVita Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $DVA

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs